Micafungin Use in Children: A Tertiary Referral Hospital Experience in the Treatment of Invasive Fungal Infections

Basit Öğe Kaydı
dc.authorscopusid57221502271
dc.authorscopusid38061964200
dc.authorscopusid55239904000
dc.authorscopusid57222327020
dc.authorscopusid57209535255
dc.authorscopusid55307654100
dc.authorscopusid56088640300
dc.contributor.authorGüner, Özenen, G.
dc.contributor.authorŞahbudak, Bal, Z.
dc.contributor.authorÖzek, G.
dc.contributor.authorBilen, N.M.
dc.contributor.authorÜmit, Z.
dc.contributor.authorTerek, D.
dc.contributor.authorPolat, S.H.
dc.date.accessioned2024-08-25T18:45:29Z
dc.date.available2024-08-25T18:45:29Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Invasive fungal infections (IFIs) are a major cause of mortality and morbidity in hospitalized pediatric patients due to limited treatment options. Micafungin has been the most recently approved echinocandin for the treatment of IFIs in children; however, the data on efficacy and adverse events in children has been limited. This study aimed to evaluate the characteristics, treatment responses, and the incidence of adverse events of the micafungin treatment in children. Material and Methods: This retrospective study was designed to evaluate all patients under 18 years old who received micafungin for treatment between January 2017-December 2019. A standardized form was used to collect demographic characteristics, underlying medical conditions, diagnosis of fungal infections, laboratory findings, prognosis, and mortality (14-day mortality, 30-day mortality). Results: We evaluated 43 episodes of 39 patients who received mica-fungin for treatment. Median age of the patients who received mica-fungin for treatment was 2.3 (10 days-17 years and six months) years. Micafungin was used for definitive treatment in 18 (41.9%) patients, for empiric treatment in 15 (34.9%) patients, and for febrile neutrope-nia in 10 (23.3%) patients. Median duration of micafungin treatment was 14 (3-53) days. Treatment efficacy was found as 79.1% in clinical response and 81.3% in mycological response. The incidence of hepat-ic adverse events was 20.9% and renal adverse events 2.3% while using micafungin for treatment. In patients who received micafungin for treatment, 14-day and 30-day mortality rates were 7% and 9.3%, respec-tively. However, these deaths were not attributable to a fungal infection (two patients died due to heart failure, and two patients died due to respiratory failure). Conclusion: We demonstrated that micafungin might be a safe and effective antifungal agent for empiric therapy and definitive therapy. Further and more extensive prospective studies to evaluate the efficiency and safety of micafungin in children are needed. © 2023, AVES. All rights reserved.en_US
dc.identifier.doi10.5578/ced.20239901
dc.identifier.endpage8en_US
dc.identifier.issn1307-1068
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85153315948en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.5578/ced.20239901
dc.identifier.urihttps://hdl.handle.net/11454/101584
dc.identifier.volume17en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofCocuk Enfeksiyon Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectchildrenen_US
dc.subjectInvasive fungal infectionsen_US
dc.subjectmicafunginen_US
dc.subjectalanine aminotransferaseen_US
dc.subjectalkaline phosphataseen_US
dc.subjectamphotericin B lipid complexen_US
dc.subjectaspartate aminotransferaseen_US
dc.subjectbilirubinen_US
dc.subjectcreatinineen_US
dc.subjectfluconazoleen_US
dc.subjectgamma glutamyltransferaseen_US
dc.subjectmicafunginen_US
dc.subjectvoriconazoleen_US
dc.subjectabsolute neutrophil counten_US
dc.subjectadolescenten_US
dc.subjectadverse eventen_US
dc.subjectallergyen_US
dc.subjectArticleen_US
dc.subjectbone marrow transplantationen_US
dc.subjectCandida albicansen_US
dc.subjectCandida glabrataen_US
dc.subjectCandida parapsilosisen_US
dc.subjectchilden_US
dc.subjectclinical articleen_US
dc.subjectdrug dose increaseen_US
dc.subjectfebrile neutropeniaen_US
dc.subjectfemaleen_US
dc.subjectgastrointestinal diseaseen_US
dc.subjecthematologic malignancyen_US
dc.subjecthumanen_US
dc.subjecthypokalemiaen_US
dc.subjectkidney function testen_US
dc.subjectliver function testen_US
dc.subjectliver toxicityen_US
dc.subjectmaleen_US
dc.subjectmatrix assisted laser desorption ionization time of flight mass spectrometryen_US
dc.subjectmonotherapyen_US
dc.subjectmortalityen_US
dc.subjectmortality rateen_US
dc.subjectneutropeniaen_US
dc.subjectobservational studyen_US
dc.subjectplatelet counten_US
dc.subjectprematurityen_US
dc.subjectprognosisen_US
dc.subjectprophylaxisen_US
dc.subjectradiographyen_US
dc.subjectretrospective studyen_US
dc.subjectsystemic mycosisen_US
dc.subjecttertiary care centeren_US
dc.subjectthrombocytopeniaen_US
dc.subjecttreatment responseen_US
dc.titleMicafungin Use in Children: A Tertiary Referral Hospital Experience in the Treatment of Invasive Fungal Infectionsen_US
dc.title.alternativeÇocuklarda Mikafungin Kullanımı: İnvaziv Mantar Enfeksiyonlarının Tedavisinde Üçüncü Basamak Merkez Deneyimien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu